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Low Expression of miR-424-3p 
is Highly Correlated with Clinical 
Failure in prostate Cancer
e. Richardsen1,3, S. Andersen2,4, S. Al-saad1,3, M. Rakaee  1, Y. Nordby2,5, M. I. pedersen1, 
N. Ness1, L. M. Ingebriktsen1, A. Fassina6, K. A. taskén7,9, I. G. Mills8,10, T. Donnem2,4, 
R. M. Bremnes2,4 & L. t. Busund1,3
prostate cancer (pC) is a highly heterogenous disease and one of the leading causes of mortality in 
developed countries. Recently, studies have shown that expression of immune checkpoint proteins are 
directly or indirectly repressed by microRNAs (miRs) in many types of cancers. the great advantages of 
using miRs based therapy is the capacity of these short transcripts to target multiple molecules for the 
same- or different pathways with synergistic immune inhibition effects. miR-424 has previously been 
described as a biomarker of poor prognosis in different types of cancers. miR-424 is also found to target 
both the CTLA-4/CD80- and PD-1/PD-L1 axis. In the present study, the clinical significance of miR-
424-3p expression in PC tissue was evaluated. Naïve radical prostatectomy specimens from 535 patients 
was used for tissue microarray construction. In situ hybridization was used to evaluate the expression 
of miR-424-3p and immunohistochemistry was used for CTLA-4 protein detection. In univariate- and 
multivariate analyses, low expression of miR-424-3p was significant associated with clinical failure-
free survival, (p = 0.004) and p = 0.018 (HR:0.44, CI95% 0.22–0.87). Low expression of miR-424-3p also 
associated strongly with aggressive phenotype of PC. This highlight the importance of miR-424-3p as 
potential target for therapeutic treatment in prostate cancer.
It has become increasingly evident that the immune system represents an important option for the develop-
ment of anticancer treatment. Most of the anti-cancer research has focused on immunotherapy, which aims to 
enhance antitumor immunity by blocking immune check-points (ICPs)1. In 2010 the immune therapy cancer 
vaccine sipuleucel-T was approved by the US Food and Drug Administration (FDA) for men with metastatic 
castration resistant PC (mCRPC)2 and the ongoing early phase trials of programmed cell death protein-1 (PD-1) 
inhibitors have reported promising results in prostate cancer (PC)2–4. Latest, results from a phase 1 study with 
pembrolizumab treatment in programmed cell death ligand -1 (PD-L1) positive PC, showed that the median 
response treatment time was 13.5 months, progression-free survival and overall survival were 3.5 and 7.9 months, 
respectively4. However, there have been several notably immunotherapy failures in PC and recent studies has 
demonstrated that the tumor microenvironment (TME) might be the reason for this because the TME might be 
predisposed towards immunosuppression5–8.
mRNAs (miRs) are a class of non-coding small RNA molecules and are found to be key regulators of gene 
expression which regulate metabolic- and cellular pathways for controlling cell proliferation, differentiation and 
survival. Recently, studies of the relationship between miRs, ICPs and how miRs modulate the immunity via ICPs, 
have received increasing attention9–12. ICP molecules can up- or downregulate important signals that can lead to 
modulate different immune actions9. In a cancerous tissue, the tumor cells can dysregulated the expression of 
ICPs on immune cells in order to suppress the antitumor immune response which can lead to immune resistance, 
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consequently aiding in progression of various cancers13,14. In a recent study by Xu et al. in ovarian cancer cell 
lines and in ovarian cancer tissues, they found that the expression of miR-424 was negatively correlated with 
the expression level of cytotoxic T-lymphocyte associated protein 4 (CTLA-4), PD-L1 and CD80. Further, they 
observed higher activity of T cells and reversion on chemoresistancy following by restoration of miR-42412, which 
increased the progression-free survival time. If miR-424 biologically mimics the activity to the expression of ICPs 
as a regulator of both directly and the indirectly control mechanisms this will be important knowledge. MiRs 
which targets multiple checkpoint molecules could be unique therapeutic targets because they mimic the block-
ade with multiple immune checkpoint inhibitors which found to be superior to single antibody therapy12,14–16. 
CTLA-4 is a protein receptor that downregulates immune responses and appears on the surface of T cells which is 
activated on by contact with antigen and acts to inhibit lymphocytes response12. Moreover, in a tumor progression 
situation the miR-424 can directly block the binding of PD1/PDL1 and CD80/CTLA-4 action and thereby induce 
tumor suppression17.
Specifically, based on published data showing that miR-424 is inversely correlated with CTLA-4 we wanted to 
investigate the prognostic significance of miR-424-3p and CTLA-4 in untreated radical prostatectomy specimens 
(no = 535) with extensive follow-up. Further we analysed their potential role in a large PC cohort and correla-
tion to clinicopathological variables and previous published biomarkers, PD-L1/PD-1 and subsets of T cells was 
assessed.
Materials and Methods
patients. Radical prostatectomy specimens of 671 patients were retrospectively collected from two differ-
ent Health care regions in Norway: Northern Norway Regional Health Authority and Central Norway Regional 
Health Authority. The inclusion time period was from 1995 to 2005. All patients were diagnosed with adenocarci-
noma. Of these, 131 patients were excluded due to (1) neoadjuvant therapy prior surgery, (2) other types of cancer 
5 years before PC diagnosis, (3) missing clinical follow-up data, and (4) inadequate paraffin-embedded tissue 
blocks, leaving 535 prostatectomy specimens available for investigation. None of the patients had received pre-op-
erative hormonal therapy. From the patients’ records the following variables were registered: demographical data, 
age at surgery, surgical procedures, preoperative serum PSA level, postoperative therapy (radio-, hormonal- and/
or chemotherapy), and outcome data until the last follow-up date December 31, 2015. Median follow-up was 12.4 
years (range 1.5–20 years). Biochemical failure-free survival (BFFS) was calculated as time from surgery to last 
follow-up (FU) date, or date with postoperative PSA ≥ 0.4 ng/ml or intervention with adjuvant therapy. Clinical 
failure-free survival (CFFS) was defined as clinically palpable tumor recurrence or metastasis verified by radiol-
ogy. Prostate cancer specific death free survival (PCDFS) was defined as death caused by PC stated in the patient’s 
journal. Detailed information regarding the cohort are previously published18.
Tissues and tissue microarray construction (TMAs). Tumor tissue consisting of formalin-fixed 
paraffin-embedded tissue blocks from prostatectomy specimens were used. One experienced uro-pathologists 
(ER) re-evaluated the tumors and classified them according to the recent updated Gleason grading system19,20 and 
staged according to the new guidelines21. For high-throughput molecular investigation we used TMA and twelve 
TMA blocks were constructed. From paraffin-embedded blocks the uro-pathologist (ER) identified and marked 
the most representative areas of viable neoplastic epithelial cells and adjacent tumor stromal areas. The detailed 
methodology has been reported previously21. Briefly, we used a 0.6 mm-diameter stylet, and the study specimens 
were routinely sampled with duplicate cores samples from different areas of neoplastic tissue and tumor stroma 
(totally 4 cores for each patient).
In situ hybridization (ISH). Chromogenic ISH was performed on Ventana Discovery Ultra instrument 
(Ventana Medical Inc, Arizona, USA). Buffers and detection reagents were purchased from Roche (Basel, 
Switzerland). miRCURY LNA detection probe and controls was from Exiqon (Vedbaek, Denmark). Exiqon 
validated the LNATM oligonucleotides by Capillary Electrophoresis (EC) and High-Performance Liquid 
Chromotography (HPLC) and confirmed the identity of compounds using Mass Spectrometry.
optimization of method and probes. To prevent RNA degradation, we used RNAse-free water in buffers 
during the sectioning. Probe concentrations and unmasking pretreatments was tested on one TMA multi-organ 
block to optimize the detection method. Hybridization temperatures for each probe and controls was tested and 
a set with RNA melting temperature as a guideline. The sensitivity level of ISH method was ensured by the use 
of U6 snRNA control probe at 0.5 nM concentration. Nuclear signal at concentrations between 0.1–2.0 nM for 
U6 was considered to have the best sensitivity. U6 also indicated low degree of RNA degradation by visualizing 
strong nuclear staining by light microscope. Scramble miR negative control probe gave no unspecific positive 
staining in prostate TMA cores. For validation purpose, miR-424-3p staining expression was investigated on one 
multi-organ control TMA block which included both normal and tumor tissues (Fig. 1).
ISH procedure. The ISH protocol steps are documented in our previous study22. In detail for miR-424-3p 
probing, TMA blocks were sectioned with 4 µm thickness and incubated at 60 °C. Liquid Coverslip oil (Roche, 
5264839001) was used to protect sections from drying and also securing proper incubation of regents across slide. 
Deparaffinization was performed by EZ Prep buffer (Roche, 5279755001) at 68 °C (3 × 12 min). Target unmasking 
to disengage cross linking effect of formalin fixation was done at 95 °C with CC2 buffer (Roche, 6414575001) for 
40 minutes to allow the DIG labeled LNATM probes to hybridize to the patient microRNA sequence. After target 
unmasking, the sections were rinsed with Reaction Buffer (Roche, 5353955001) and then RiboWash, SSPE buffer 
(Roche, 5266262001). Probes were diluted in a 1:1 solution of Exiqon microRNA ISH buffer (9000) and Elix 
RNAse free water to their final concentration. 10 nM miR-424-3p (Exicon, 611050-360), 10 nM Scramble miR 
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(Exiqon, 99004-15) negative control probe and 0.5 nM U6 (Exiqon, U6, 99002-15) positive control probe was 
used in this study.
Denaturation of the LNA-probes was achieved at 8 min at 90 °C to get optimal hybridization conditions. 
Hybridization of the LNA-probes miR-424-3p, was performed in the instrumnet for 60 min at 55 °C for miR-
424-3p, 57 °C for scramble miR and 55 °C for U6. Stringent washes was done 2 × 8 min with 2.0X RiboWash, 
SSPE buffer with same temperatures as used under hybridization for each probe. Blocking against unspecific 
bindings then followed with blocking solution (Roche, 5268869001) for 16 min. at 37 °C. Alkaline phosphatase 
(AP)-conjugated anti DIG (Anti-DIG-AP Multimer, Roche, 07256302001) was incubated for 20 min at 37 °C for 
immunologic detection. After rinsing substrate enzymatic reactions was carried out with NBT/BCIP (CromoMap 
Blue kit, Roche, 526661001) 60 min. at 37 °C to give a blue precipitate to detect the microRNA. Sections were 
Figure 1. Panel of miR-424-2p in situ hybridization staining. (A) Strong nuclear staining of miR-424-3p, 
Gleason grade group 4 (4 + 4); (B) Weak nuclear staining of miR-424-3p, Gleason grade group 1 (3 + 3); (C) 
Normal prostatic tissue with some nuclear staining of miR-424-3p; (D) U6 control staining; (E) Positive tissue 
control: papillary renal cell carcinoma; (F) Negative tissue control: normal human brain tissue. (magnification 
20x).
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again rinsed and counterstained 4 min with Red Stain II (Roche, 5272017001). After manual washing in tap water, 
dehydration was done by increasing gradients of ethanol solutions to Xylene. In the end, sections were mounted 
with Histokitt mounting medium.
Immunohistochemistry (IHC). Discovery-Ultra was used for IHC analysis of CTLA-4 expression. 
Mouse monoclonal CTLA-4 (CD-152) antibody, clone 14D3, (eBioscience, cat#14-1529-80), was used in this 
study. Antibody concentrations and unmasking pretreatments was tested using both TMA and whole tissue 
slides. Positive and negative tissue controls, and negative subclass isotype-matched control antibody (Biolegend, 
cat#400203) was included.
Deparaffinization was performed in EZ Prep buffer (Roche, 5279755001) at 68 °C (3 × 12 min). Target 
unmasking to disengage cross linking effect of formalin fixation was done at 95 °C with CC1 buffer (Roche, 
6414575001) for 24 minutes. Endogenous peroxidase was blocked for 8 minutes by Discovery inhibitor CM 
(Roche, 05266645001). Mouse monoclonal CTLA-4 antibody (1:100 dilution) was incubated for 32 minutes at 
36 °C. Secondary multimer antibody OmniMap anti-Ms HRP (Roche, 5269652001) followed as immunologic 
detection for 16 minutes and substrate reaction was done with Discovery ChromoMap DAB detection kit (Roche, 
526645001). All sections were counterstained for 16 minutes with hematoxylin (Roche, 5266726001) and post 
counterstained for 4 minutes with bluing Reagent, (Roche, 5266769001).
Antibody validation. Validation and details of western blotting have been presented in our previous lung 
cancer study23. Briefly, CTLA-4 protein expression was detected using the CD-152 mouse monoclonal anti-
body (1:100 dilution, eBioscience, Cat#14-1529-80). To validate the specificity of the antibody on Western blot, 
HEK293 transfectant cell lysates with and without CTLA-4 expression were analysed as described. Actin was 
used as loading control on the Western Blot by using an anti-actin antibody (1:10000 dilution, Sigma-Aldrich, 
Cat#A2066).
The specificity of the antibody in IHC analyses was verified by staining multi-organ TMA as negative and 
positive controls. We included TMA tissue controls (positive: papillary renal cell carcinoma and negative: normal 
brain) and negative method controls in each staining run. Each TMA slide, from the main cohort, additionally 
contained normal prostate epithelium and stroma that acted as internal controls. As negative staining controls—
the primary antibody was omitted to observe whether the secondary antibody or some other elements in the 
system are reacting with a component of the tissue.
Scoring and expression of miR-424-3p and CTLA-4. The samples were anonymized and independently scored 
by two observers (miR-424-3p: ER, SAS, CTLA-4: ER, MR). During the assessment of a given score, the two 
observers were blinded to each other’s findings, clinicopathological variables, and outcomes. In case of disagree-
ment (scoring difference >1) the core was re-examined and consensus was reached. miR-424-3p was expressed 
in the nuclei of tumor cells. The staining intensity was all over strong (Fig. 1A,B). We also observed some staining 
in normal cells, but the staining intensity was mostly weak (Fig. 1C) For miR-424-3p, the percentage of positively 
blue-coloured tumor epithelial cell nuclei was counted, and subsequently given a score using the following sys-
tem: 0 = 0%, 1 = 1–2.5%, 2 = 2.6–4%, 3 ≥5%. The scoring for miR-424-3p was then dichotomized to low vs high 
score, defined as mean <3.62 (low score) and ≥3.62 (high score). CTLA-4 was investigated in epithelial tumor 
cells (TE), adjacent tumor stromal areas (TS) and TE + TS as one compartment. The staining of CTLA-4 positive 
cells was overall weak, relatively homogenous and granular in tumor tissue, both in the TE and TS (Fig. 2). In 
most cases the staining was located in the cytoplasm. Because of homogenous staining the percentage (density) 
did not add valuable information to the score and was therefore not included. Intensity of CTLA-4 staining was 
scored as no signal = 0, weak = 1, moderate = 2 and strong = 3 (Fig. 2A–C). For CTLA-4 (TE + TS) low score was 
defined as <2.29 (mean), and a high score as ≥2.29.
Cut-off values for dichotomization were chosen according to a minimal p-value (p < 0.005) approach securing 
statistically significant number in each group. For both, the optimal threshold value was defined as mean.
statistical methods. The SPSS software, version 24 (IBM, SPSS Inc., Chicago, IL, USA) was used for all 
analyses. Inter-observer reliability between the pathologists (ER/SAS, ER/MR) was tested by use of a two-way ran-
dom effect model (absolute agreement). Spearman correlation test was used to examine the association between 
miR-424-3p, CTLA-4, clinicopathological variables, subsets of T cells24, PD-1 and PD-L125. In univariate anal-
ysis of survival according to miR-424-3p and CTLA-4, the Kaplan-Meier method were applied, and statistically 
Figure 2. Panel of CTLA-4 immunohistochemical staining. (A) Strong nuclear staining expression of CTLA-
4, Gleason grade group 1 (3 + 3); (B) Moderate staining expression, Gleason grade group 4 (4 + 4); (C) Weak 
staining expression, Gleason grade group 5 (4 + 5). (magnification 20x).
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significant differences between survival curves were analyzed by the log-rank test. For multivariate analyses the 
Cox-regression analysis was used with a proportional model, testing the probability for stepwise entry at 0.05 and 
stepwise removal was set at 0.05 and 0.10, respectively. P-values < 0.05 was considered statistically significant.
ethics. This study was approved by the Regional Committees for Medical Health Research Ethics (REK Nord), 
Ref. no: 2009/1393. A mandatory re-approval was conducted in 2016 and 2019. REK Nord considered written 
consent is not necessarily due to retrospective nature of this study, and as the majority of the material is more than 
10 years old and many of the patients deceased. The Norwegian Centre for Research Data (NSD) approved the 
assembly of the database. Prior the study, all included was made anonymous and given a trial number which were 
used during the study. The reporting of clinicopathological information, survival data and biomarker expression 
status was conducted in accordance with the REMARK guidelines25.
Results
patient characteristics. Table 1 provide the clinical- and histopathological data for all 535 patients. Median 
age at surgery was 62 years (range 47–76). The surgical procedures were retropubic in 81% (n = 435) and perineal 
in 19% (n = 100). Gleason grade group ranged from 1 to 5; 1 (≤6), 2 (3 + 4), 3 (4 + 3), 4 (4 + 4) and 5 (≥8). Tumor 
stage included T2a to T3b. PSA was 8.8 (median range 0.7–104). At last follow-up, 200 (37%) had BF, 56 (11%) 
had CF and 18 (3.4%) had died of PC.
Correlations. ICC between the scores ER/SAS was 0.97 (CI: 0.91–0.98) and between ER/MR 0.093 (CI: 
0.89–0.98). We correlated the expression of miR-424-3p to all clinicopathological variables due to their possi-
ble association to prognosis (Table 1). We found significant correlations between mir-424-3p and the following 
clinicopathological variables: high Gleason grade group (r = 0.12, p = 0.014), Gleason grade group ≥8 (r = 0.11, 
p = 0.024), large tumor size (>20 mm, r = 0.13, p = 0.013), perineural infiltration (r = 0.11, p = 0.030) and vascu-
lar infiltration (r = 0.12, p = 0.014). CTLA-4 did not correlate to any clinicopathological variables. We also made 
correlations between miR-424-3p, CTLA-4 and our previously published ICP (PD-1/PD-L1)25 and subset of T 
cells (CD3, CD4, CD8 and CD20)24. miR-424-3p correlated significantly to CTLA-4, r = 0.10, p < 0.001, and to 
PD-L1 (TE compartment, cut-off: mean value = 0), r = 0.11, p = 0.040. CTLA-4 correlated to PD-1 (TE compart-
ment, cut-off: mean value = 1.0), r = 0.10, p = 0.054, and PD-1 (TS compartment, cut-off: mean value = 0.54), 
r = 0.16, p = 0.002). Correlation to subsets of T cells, miR-424-3p did not correlate to the prevalence of any T- 
cells. CTLA-4 correlated to CD3+ T cells (r = −0.11, p = 0.028), CD4+ T cells (r = −0.12, p = 0.009). Detailed 
information regarding PD-1/PD-L1 and the subset of T-cells, IHC, validation, scoring methods, staining proto-
col, staining localization and statistical analyses are described in detail previously22,24.
Univariate analyses. Results from the univariate analysis are presented in Table 1 and Fig. 3. The follow-
ing clinicopathological variables were significant prognostic factors for BF; pre-operative PSA (p < 0.001), pT 
stage (p < 0.001), pN stage (p < 0.001), perineural infiltration (p < 0.001), tumor size (p < 0.001), non-apical PSM 
(p < 0.001), vascular infiltration (p < 0.001), and Gleason grade group (p < 0.001). miR-424-3p and CTLA-4 (TE, 
TS, TE + TS) was not significant for BF. For CF; age (p = 0.038), PSA (p = 0.029), pT stage (p < 0.001, pN stage 
(p < 0.001), tumor size (p = 0.002), non-apical PSM (p < 0.001), vascular infiltration (p < 0.001), Gleason score 
(p < 0.001) and miR-424-3p (p = 0.004). CTLA-4 was not significant (TE + TS, p = 0.093). For PCD; preoperative 
PSA (p = 0.003), pT stage (p < 0.001), pN stage (p < 0.001) perineural infiltration (p < 0.001), non-apical positive 
surgical margin (p = 0.022) and Gleason score (p < 0.001).
Multivariate analyses. Results from the multivariate model is present in Table 2. The following clinico-
pathological variables were significant with poor BFFS: perineural infiltration, pT stage, pT3b, Gleason grade 
group, Gleason grade group ≥4, and both, apical- and non-apical PSM. Low expression of miR-424-3p (HR: 
0.44, 95% CI 0.22–0.87, p = 0.018) was associated with aggressive disease and poor CFFS together with aggressive 
feature of PC.
Discussion
In this study, we identified that low expression of the miR-424-3p was significant predictor for PC aggressiveness 
and outcome and was associated with aggressive features in PC; high Gleason grade group, large tumor size, 
perineural- and vascular infiltration. We also found that low expression of miR-424-3p was associated with worse 
clinical failure-free survival. Furthermore, a positive correlation between miR-424-3p and CTLA-4 was observed, 
indicating a functional pathway between miR-424-3p and this ICP molecule. Further, CTLA-4 was significantly 
correlated with CD3+ and CD4+ T cells. To the best of our knowledge this is the first large-scale study investi-
gating the miR-424-3p and CTLA-4 pathway in untreated human PC specimens. The strength of this study is the 
large number of patients, the long extensive clinical follow-up data and the in-situ examination of in both tumor 
epithelial cells and adjacent tumor stromal area. We did not, however, have paired normal tissue controls and we 
did not perform cell line studies for validation purpose, which are limitations to this study.
The clinical success of several anti-PD-1 and anti-CTLA-4 treatment in various malignancies has boosted the 
research of immune checkpoint pathways26–29. In PC, however these treatment modalities have been relatively 
disappointing6–8,30, and progression to a chemo-resistant, androgen-independent state is the norm. Only a small 
number of subset of patients respond to current available immunotherapies31, which may indicate that prostate 
cancer is different from immunogenic cancers as melanoma and lung25–29,32.
Recent studies have shown that PC tumor microenvironment (TME) may play an important role in explain-
ing treatment failure5–8. The major explanation so far is that the TME is largely heterogeneous and that PC is 
not a hypermutated disease as other urological cancers16 and that absence of successfully treatment modalities 
as blocking the axis of PD-1/PD-L1 and CTLA-4/CD80 expression is due to several alterations in these ICP 
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molecules9,12,13. The role of miRs as regulators of ICP molecules have been intensively investigated and discussed 
in several studies9–12 and a large body of evidence has indicated that several miRs play an important role in regu-
lation of the host immune response and ICP molecules10,11,14,16 and attention has been drawn to miRs that directly 
or indirectly controls expression of more than one ICP molecule (Fig. 4), and vice versa. Although the role of 
miR-424 in different type of cancers have been reported, these studies are conflicting, both tumor-suppressing 
and tumor promoting functions have been proposed31,33–35. Noteworthy, the understanding of miR-424 comes 
derives primarily from mechanistic studies on cell lines and animal models, little from studies on human tissues, 
or if, on human tissue the number included is limited. Additionally, many of the functionally studies were limited 
to the use of cell lines in which miR-424 were overexpressed. This may also account for the discrepancies. miR-
424 belongs to the miR-16 family and members of this family have previously shown to be fundamental targets 
Characteristics
Patients 
n (%)
BFFS (n = 200) 
5-year EFS (%) P
CFFS (n = 56) 10-
year EFS (%) P
DSS (n = 18) 
10-year EFS (%) P
Age 0.237 0.038 0.404
<65 year 357 (37) 77 94 98
≥65 year 178 (33) 70 91 98
Preop. PSA <0.001 0.029 0.003
PSA < 10 308 (57) 81 95 99
PSA > 10 221 (42) 68 89 97
pT-stage <0.001 <0.001 0.001
pT2 374 (70) 83 97 99
pT3a 114 (21) 61 87 98
pT3b 47 (9) 43 74 91
pN-stage <0.001 <0.001 <0.001
NX 264 (49) 79 96 99
N0 268 (50) 72 90 97
N1 3 (1) 0 33 67
PNI <0.001 <0.001 <0.001
No 401 (75) 80 96 99
Yes 134 (25) 60 83 95
Tumor size <0.001 0.002 0.085
<20 mm 250 (47) 83 96 99
≥20mm 285 (53) 68 90 97
PSM 0.049 0.198 0.843
No 249 (47) 81 90 98
Yes 286 (53) 69 96 98
Apical PSM 0.063 0.427 0.128
No 381 (71) 82 96 99
Yes 154 (29) 57 85 96
Non-apical PSM <0.001 <0.001 0.022
No 381 (71) 82 96 99
Yes 154 (29) 57 85 96
LVI <0.001 <0.001 <0.001
No 492 (92) 77 95 99
Yes 43 (8) 47 70 90
Surgical proc. 0.466 0.308 0.965
Retropubic 435 (81) 77 92 98
Perineal 100 (19) 68 95 99
Gleason grade 
Group <0.001 <0.001 <0.001
1 (≤ 6) 183 (34) 83 98 99
2 (3 + 4) 219 (41) 77 94 99
3 (4 + 3) 81 (15) 70 90 96
4 (4 + 4) 17 (3) 58 86 94
5 (>8) 35 (7) 36 65 91
Table 1. Prognostic clinicopathologic variables as predictors of BF, CF and DSS in 535 prostate cancer patients 
(univariate analysis; log-rank test). Abbreviations: BFFS = biochemical failure-free survival; CFFS = clinical 
failure-free survival; DSS = disease specific survival; EFS = event free survival; LVI = lympho-vascular 
infiltration; PNI = perineural infiltration; preop = preoperative; PSA = prostate specific antigen; PSM = positive 
surgical margin; Surgical proc. = surgical procedure.
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for cell cycle arrests and apoptosis15. Furthermore, miR-424 is found to be predicted to target many miRs, epi-
dermal growth factor receptor (EGFR), Twist and DNA damage-repair genes17. They evaluated the finding from 
in vitro studies by IHC of clinical samples and found that miR-424 upregulation was negatively correlated with 
EGFR expression17. The same group also reported that a downregulation of miR-424 was associated with adverse 
prognostic factors such as advanced clinical stages, nodal metastasis, and high pathological grades17. Recently, 
Zhang et al. reported a functional role of miR-424/Akt3/E2F3 axis in hepatocellular carcinoma development, sug-
gesting that miR-424 could be a potential indicator of prognosis36. In PC there is only a limited number of studies 
and they all has limitation mentioned above. In a study by Dallavalle et al. miR-424 expression was evaluated in 
both normal- (no = 21) and PC tissues (no = 48) and cell lines37, miR-424 was found to be highly expressed in 
metastatic subclones of DU145 cells and promoted the EMT and metastatic phenotype, which is consistent with 
Banyard et al. study38. In the latter, they found that stable MiR-424 expression reduced epithelial-mesenchymal 
progression. Review- and met-analyses miR-screening studies on different PC cell lines and miR-424 did not 
report any significant findings39–41. Palladine et al. linked miR-424 to the innate immune system by activate 
monocytes to differentiate and activate42 however, here we failed to correlate MiR-424-3p to any monocytes.
Based on the above-mentioned mechanistic studies and a recently published study by Xu et al.12 miR-424 is 
appearing as one novel and important biomarker that has the potential to predict tumor progression and treat-
ment target option. In the study by Xu et al. they found that low levels of miR-424(322) was associated with 
chemoresistance and that miR-424(322) was inversely correlated with the PD-1/PD-L1 and CTLA-4/CD80 path-
ways, by inhibiting PD-L1 and CD8012.
In general, the lack of data regarding the targets of miR-424 hampers a full understanding of the biological 
functions of aberrant miR-424.
In PC, the knowledge about of miR-424 is very limited. Our study is the first large-scale study investigating the 
miR-424-3p and CTLA-4 pathway in human prostatectomy specimens (no = 535), we also abled to investigate 
the correlation to PD1, PD-L1 and subset of T cells. Herein, we found that a low expression of miR-424-3p was 
significantly correlated to aggressive PC phenotype, worse clinical outcome and reduced time for clinical failure, 
which is in line with previous in vitro and in vivo studies36,38,42–46. We also identified a correlation between miR-
424-3p, CTLA-4 and PD-L1, which is in accordance with one previous report12.
What is well known is that PC tissue is marked by large T cell inflammatory infiltrates within TE and TME 
participating in host defence mechanisms against tumor cells40,41 and that PD-1/PD-L1 pathway has a crucial role 
in the regulating of T cell activation during inflammatory processes33, in contrast to CTLA-4, which inhibits T cell 
activityduring the T cell priming phase41,42. Here, we found that miR-424-3p correlated significantly to CTLA-4 and 
to PD-L1 (only in TE). Furthermore, CTLA-4 correlated very well to PD-1 in TE and PD-1 TS separately, and also 
as one compartment (TE + TS). We did not find any correlation between miR-424-3p to subset of T cells, however, 
CTLA-4 were correlated to CD3+ T cells and CD4+ T cell. Some of these findings are in correlation with others5–8,12.
To date, there are conflicting explanation for the suboptimal responses to check-point inhibitors in PC. Studies 
have suggested that the high immunogenicity of PC is one reason, because PC is a slow-growing disease allowing 
time for a clinically relevant response.
Here, we argue for the importance of miR-424-3p expression alone, and in close correlation with CTLA-4 as 
negative factors for worse outcome in PC. In this study we also had the advantages of investigating TE, TS and 
TE + TS separately which might can be of interest to better understand the reciprocal interplay between TE and 
TME and their interactions with the ICPs.
Figure 3. Association with prostate cancer outcome and miR-424-3p. Kaplan-Meier survival curves displaying 
clinical failure-free survival (CFFS) dichotomized into high vs low expression of miR-424-3p. Low score was 
defined as <3.62 and high score to ≥3.62.
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In conclusion, here we demonstrate that low expression of miR-424-3p is associated with reduced clinical 
failure-free survival and worse outcome in PC. Furthermore, we found a significant correlation between miR-
424-3p and CTLA-4. Our findings indicate that the miR-424-3p/CTLA-4 and miR-424-3p/PD-1 pathways are 
important in PC and that these interactions may have potential as a therapeutic target.
Characteristic No
BF (200 events) CF (56 events) PCD (18 events)
HR 95% CI P HR 95% CI P HR 95% CI P
Age NS NS NS
   ≤65 years 264
   >65 years 135
pT-stage 0.035 NS NS
   pT2 275 1
   pT3a 85 1.42 (0.69–2.86) 0.343
   pT3b 39 0.52 (0.32–0.83) 0.006
Preoperative PSA NS NS 0.023
   PSA <10 224 1
   PSA >10 175 0.21 (0.06–0.81)
Gleason grade group 0.016 0.001 NS
   1 (3+3) 126 1 1
   2 (3+4) 231 2.13 (0.47–9.70) 0.329 0.19 (0.03–1.19) 0.076
   3 (4+3) 115 2.90 (0.66–12.82) 0.161 0.56 (0.12–2.62) 0.465
   4 (4+4) 24 4.25 (0.82–22.13) 0.085 1.27 (0.20–8.18) 0.804
   5 (≥9) 3 4.57 (1.00–20.80) 0.050 2.32 (0.49–11.03) 0.290
Tumor size NS NS NS
   0–20 mm 169
   >20 mm 230
PNI 0.008 NS NS
   No 298 1
   Yes 101 0.62 (0.44–0.83)
Non-apical PSM 0.003 NS NS
   No 284 1
   Yes 115 0.58 (0.41–0.83)
Apical PSM 0.02 NS NS
   No 247 1
   Yes 152 1.52 (1.07–2.15)
Vascular infiltration NS 0.008 NS
   No 365 1
   Yes 34 0.39 (0.19–0.79)
miR-424-3p NS 0.018 NS
   Low 200 1
   High 204 0.44 (0.22–0.87)
Table 2. miR-424-3p expression and significant clinicopathological variables (Multivariate model, 
Cox regression, backward conditional). Abbreviations: BF = biochemical failure; CF = clinical failure; 
PCD = prostate cancer death; PSA = prostate specific antigen; PNI = perineural infiltration, PSM = positive 
surgical margin; NS = not significant.
Figure 4. Schematic presentation of the interaction between miR-424 and the immune checkpoint proteins, 
PD1/PD-L1 and CTLA-4.
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